| Literature DB >> 30936629 |
Ryota Kobayashi1, Yuto Hashimoto2, Takanobu Okamoto3.
Abstract
The present study investigated the acute effect of a footbath on increases in arterial stiffness after glucose ingestion in healthy young women. Nine healthy young women (aged 18.4 ± 0.2 years; mean ± SE) completed three trials in random order. They started a footbath before 75-g oral glucose ingestion, a footbath after 75-g oral glucose ingestion and no footbath (control) trials. Aortic (carotid-femoral) and leg (femoral-ankle) pulse wave velocity, the carotid augmentation index, carotid, brachial and ankle blood pressure, heart rate, blood glucose levels, insulin levels and sublingual temperature were measured before (baseline) and at 15, 30, 60 and 90 min after the 75-g oral glucose ingestion. Aortic pulse wave velocity and brachial systolic blood pressure did not change from baseline to after the 75-g oral glucose ingestion in all trials. Leg pulse wave velocity and ankle systolic blood pressure were increased from baseline to after the 75-g oral glucose ingestion in the footbath after glucose ingestion and control trials, but not in the footbath before glucose ingestion trial. These results suggest that a footbath effectively suppresses the increase in leg arterial stiffness after glucose ingestion when implemented before glucose ingestion.Entities:
Keywords: ankle blood pressure; footbath; glucose ingestion; leg arterial stiffness
Year: 2019 PMID: 30936629 PMCID: PMC6436038 DOI: 10.3164/jcbn.18-71
Source DB: PubMed Journal: J Clin Biochem Nutr ISSN: 0912-0009 Impact factor: 3.114
Subject characteristics (n = 9)
| Variable | Value |
|---|---|
| Age (years) | 18.4 ± 0.2 |
| Height (cm) | 158.4 ± 1.2 |
| Weight (kg) | 53.8 ± 2.8 |
| Body fat (%) | 28.4 ± 1.2 |
| BMI (kg/m2) | 21.3 ± 1.0 |
| LBM (kg) | 39.7 ± 2.0 |
Values are mean ± SE. BMI, body mass index; LBM, lean body mass.
Fig. 1Study design. Aortic and leg PWV, carotid AIx, brachial, ankle and carotid BP, HR, BG and insulin levels and sublingual temperature were measured before (baseline, −30 min) and at 15, 30, 60 and 90 min after the 75-g oral glucose ingestion. PWV, pulse wave velocity; AIx, augmentation index; BP, blood pressure; HR, heart rate; BG, blood glucose; FB→G trial, footbath at 30 min before the 75-g oral glucose ingestion trial; G→FB trial, footbath at 15 min after the 75-g oral glucose ingestion trial; No FB trial, no footbath before and after the 75-g oral glucose ingestion trial.
Fig. 2Change in aortic PWV (A) and leg PWV (B) before (baseline, −30 min) at 15, 30, 60 and 90 min after the 75-g oral glucose ingestion in all trials. Values are mean ± SE. PWV, pulse wave velocity; FB→G trial, footbath at 30 min before the 75-g oral glucose ingestion trial; G→FB trial, footbath at 15 min after the 75-g oral glucose ingestion trial; No FB trial, no footbath before and after the 75-g oral glucose ingestion trial. ap<0.05 vs baseline. bp<0.05 and bbp<0.01 vs No FB trial, cp<0.05 vs G→FB trial.
Changes in brachial SBP, MBP and DBP before (baseline, –30 min) and after glucose ingestion in all trials
| Variable | Trial | Baseline (−30 min) | 15 min | 30 min | 60 min | 90 min |
|---|---|---|---|---|---|---|
| Brachial SBP (mmHg) | FB→G trial | 100.1 ± 2.1 | 101.1 ± 1.0 | 103.9 ± 1.9 | 102.0 ± 2.3 | 102.0 ± 3.0 |
| G→FB trial | 101.9 ± 3.3 | 101.4 ± 1.7 | 101.2 ± 1.1 | 102.2 ± 0.9 | 101.1 ± 2.5 | |
| No FB trial | 100.1 ± 1.9 | 101.3 ± 1.9 | 101.2 ± 0.6 | 100.8 ± 1.6 | 101.7 ± 1.1 | |
| Brachial MBP (mmHg) | FB→G trial | 72.1 ± 2.1 | 73.0 ± 1.5 | 73.9 ± 1.5 | 73.0 ± 1.6 | 72.6 ± 1.5 |
| G→FB trial | 73.0 ± 2.3 | 74.9 ± 2.6 | 75.0 ± 2.2 | 73.5 ± 1.6 | 72.9 ± 1.6 | |
| No FB trial | 72.9 ± 2.4 | 74.6 ± 2.0 | 75.8 ± 1.8 | 73.0 ± 1.6 | 74.3 ± 1.3 | |
| Brachial DBP (mmHg) | FB→G trial | 58.1 ± 2.4 | 58.9 ± 2.0 | 58.9 ± 1.6 | 58.1 ± 1.7 | 57.9 ± 1.1 |
| G→FB trial | 58.5 ± 2.1 | 59.6 ± 2.2 | 59.7 ± 1.6 | 59.1 ± 1.6 | 58.3 ± 1.1 | |
| No FB trial | 58.3 ± 2.4 | 59.3 ± 1.9 | 60.1 ± 1.7 | 58.2 ± 1.5 | 58.8 ± 1.2 |
Values are mean ± SE. SBP, systolic blood pressure; MBP, mean blood pressure; DBP, diastolic blood pressure; FB→G trial, footbath at 30 min before the 75-g oral glucose ingestion trial; G→FB trial, footbath at 15 min after the 75-g oral glucose ingestion trial; No FB trial, no footbath before and after the 75-g oral glucose ingestion trial.
Changes in ankle SBP, MBP, DBP, carotid SBP, HR, carotid AIx and sublingual temperature before (baseline, −30 min) and after glucose ingestion in all trials
| Variable | trial | Baseline (−30 min) | 15 min | 30 min | 60 min | 90 min |
|---|---|---|---|---|---|---|
| Ankle SBP (mmHg) | FB→G trial | 110.6 ± 2.2 | 108.2 ± 2.8d,e | 111.1 ± 2.1d | 111.1 ± 2.3d | 111.3 ± 1.5dd |
| G→FB trial | 110.3 ± 4.2 | 120.3 ± 2.4aa | 113.0 ± 2.7b | 114.7 ± 3.3 | 114.6 ± 1.7d | |
| No FB trial | 110.8 ± 3.1 | 120.5 ± 3.3aa | 121.0 ± 2.5aa | 121.6 ± 2.3aa | 121.6 ± 1.6a | |
| Ankle MBP (mmHg) | FB→G trial | 73.5 ± 1.8 | 72.2 ± 2.1d,ee | 74.5 ± 1.6d | 74.1 ± 1.5d | 74.3 ± 1.0 |
| G→FB trial | 73.7 ± 2.8 | 81.6 ± 1.9aa | 76.7 ± 1.7 | 76.7 ± 2.1b | 78.1 ± 1.9 | |
| No FB trial | 73.2 ± 1.8 | 81.2 ± 2.0aa | 82.9 ± 2.4aa | 79.7 ± 1.6aa | 75.6 ± 2.8cc | |
| Ankle DBP (mmHg) | FB→G trial | 54.9 ± 1.7 | 54.3 ± 1.9d,e | 56.1 ± 1.5d | 55.6 ± 1.2d | 55.9 ± 1.3 |
| G→FB trial | 55.4 ± 2.4 | 62.2 ± 1.9aa | 58.5 ± 1.7 | 57.6 ± 1.7b | 58.3 ± 1.7 | |
| No FB trial | 54.5 ± 1.7 | 61.5 ± 1.9aa | 62.5 ± 1.8aa | 61.1 ± 1.4aa | 56.3 ± 2.7cc | |
| Carotid SBP (mmHg) | FB→G trial | 113.3 ± 2.6 | 114.1 ± 2.2 | 114.9 ± 2.4 | 112.9 ± 4.0 | 112.3 ± 3.4 |
| G→FB trial | 113.0 ± 4.3 | 115.3 ± 3.4 | 115.6 ± 3.2 | 113.8 ± 2.7 | 113.2 ± 5.8 | |
| No FB trial | 113.4 ± 2.9 | 115.8 ± 3.2 | 116.9 ± 4.5 | 114.3 ± 5.5 | 113.4 ± 2.5 | |
| HR (beats/min) | FB→G trial | 58.2 ± 2.2 | 62.0 ± 2.2 | 63.8 ± 2.5 | 61.9 ± 2.3 | 61.9 ± 2.0 |
| G→FB trial | 58.1 ± 2.6 | 61.9 ± 2.7 | 63.7 ± 3.5 | 61.8 ± 2.4 | 61.9 ± 2.4 | |
| No FB trial | 58.0 ± 2.1 | 62.4 ± 3.0 | 63.9 ± 2.3 | 62.1 ± 2.9 | 62.0 ± 2.8 | |
| Carotid AIx (%) | FB→G trial | −15.8 ± 3.6 | −20.0 ± 3.0 | −20.5 ± 3.4 | −19.2 ± 3.2 | −15.9 ± 4.1 |
| G→FB trial | −15.6 ± 3.8 | –17.8 ± 4.4 | −22.2 ± 4.4 | −14.2 ± 3.4 | −15.0 ± 4.2 | |
| No FB trial | −15.7 ± 3.7 | −19.8 ± 4.8 | −26.5 ± 5.5 | −21.3 ± 3.7 | −16.9 ± 3.1 | |
| Sublingual temperature (°C) | FB→G trial | 36.7 ± 0.1 | 36.6 ± 0.1 | 36.6 ± 0.1 | 36.4 ± 0.1 | 36.3 ± 0.1 |
| G→FB trial | 36.7 ± 0.1 | 36.4 ± 0.1 | 36.6 ± 0.1 | 36.4 ± 0.1 | 36.3 ± 0.2 | |
| No FB trial | 36.8 ± 0.1 | 36.4 ± 0.1 | 36.6 ± 0.1 | 36.4 ± 0.1 | 36.4 ± 0.2 |
Values are mean ± SE. SBP, systolic blood pressure; MBP, mean blood pressure; DBP, diastolic blood pressure; HR, heart rate; AIx, augmentation index; FB→G trial, footbath at 30 min before the 75-g oral glucose ingestion trial; G→FB trial, footbath at 15 min after the 75-g oral glucose ingestion trial; No FB trial, no footbath before and after the 75-g oral glucose ingestion trial. ap<0.05 and aap<0.01 vs baseline. bp<0.05 and bbp<0.01 vs 15 min. ccp<0.01 vs 30 min. dp<0.05 and ddp<0.01 vs No FB trial. ep<0.05 and eep<0.01 vs G→FB trial.
Changes in BG and insulin levels before (baseline, −30 min) and after glucose ingestion in all trials
| Variable | Trial | Baseline (−30 min) | 15 min | 30 min | 60 min | 90 min |
|---|---|---|---|---|---|---|
| BG level (mg/dl) | FB→G trial | 86.8 ± 5.5 | 123.0 ± 6.5aa | 122.6 ± 7.2 | 121.7 ± 8.0 | 116.8 ± 9.8 |
| G→FB trial | 83.4 ± 1.9 | 132.9 ± 5.3aa,b | 127.0 ± 9.0a | 122.7 ± 8.3a | 117.3 ± 5.8 | |
| No FB trial | 82.3 ± 2.3 | 132.8 ± 5.8aa,b | 139.2 ± 15.3aa,b | 141.9 ± 15.1aa,b | 120.8 ± 15.2a | |
| Insulin level (µIU/ml) | FB→G trial | 5.4 ± 0.9 | 35.7 ± 6.7aa | 36.2 ± 6.0b | 33.4 ± 4.4 | 32.5 ± 4.0 |
| G→FB trial | 5.5 ± 0.6 | 40.7 ± 5.4aa,b | 35.0 ± 5.4aa | 33.1 ± 5.1 | 31.9 ± 3.7 | |
| No FB trial | 4.6 ± 0.8 | 44.7 ± 4.1aa,b | 52.2 ± 10.0aa,b | 52.3 ± 14.2aa,b | 46.0 ± 14.0aa,b |
Values are mean ± SE. BG, blood glucose; FB→G trial, footbath at 30 min before the 75-g oral glucose ingestion trial; G→FB trial, footbath at 15 min after the 75-g oral glucose ingestion trial; No FB trial, no footbath before and after the 75-g oral glucose ingestion trial. ap<0.05 and aap<0.01 vs baseline. bp<0.05 vs FB→G trial.